Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Jun-30-23 | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Revenues: |
| Protein Sciences | 845.7 | 832.3 | 704.6 | 555.4 | 543.2 | 482.4 | 419.4 | |
| Diagnostics and Genomics | 292.6 | 274.8 | 227.7 | 184.5 | 171.7 | 161.2 | 143.7 | |
| Biotechnology | | | | | | | | 317.3 |
| Other | | | | | | | | 181.7 |
| Total revenues | 1,136.7 | 1,105.6 | 931.0 | 738.7 | 714.0 | 643.0 | 563.0 | 499.0 |
| Revenue growth [+] | 2.8% | 18.7% | 26.0% | 3.5% | 11.0% | 14.2% | 12.8% | 10.3% |
| Protein Sciences | 1.6% | 18.1% | 26.9% | 2.2% | 12.6% | 15.0% | | |
| Diagnostics and Genomics | 6.5% | 20.7% | 23.4% | 7.5% | 6.5% | 12.1% | | |
| Biotechnology | | | | | | | | 2.9% |
| Protein Platforms | | | | | | | | 16.7% |
| Cost of goods sold | 366.9 | 349.1 | 298.2 | 255.5 | 240.5 | 210.9 | 188.5 | 162.4 |
| Gross profit | 769.8 | 756.5 | 632.9 | 483.2 | 473.5 | 432.1 | 374.5 | 336.7 |
| Gross margin | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% |
| Selling, general and administrative | 378.4 | 372.8 | 325.0 | 260.6 | 264.4 | 240.6 | 200.4 | 140.9 |
| Research and development | 92.5 | 87.1 | 70.6 | 65.2 | 62.4 | 55.3 | 53.5 | 45.2 |
| EBITDA [+] | 406.2 | 397.7 | 325.0 | 240.2 | 224.9 | 200.6 | 180.6 | 193.4 |
| EBITDA growth | 2.1% | 22.3% | 35.3% | 6.8% | 12.1% | 11.1% | -6.6% | 4.9% |
| EBITDA margin | 35.7% | 36.0% | 34.9% | 32.5% | 31.5% | 31.2% | 32.1% | 38.7% |
| Depreciation | 29.7 | 26.9 | 87.7 | 82.7 | 19.5 | 64.5 | 60.0 | 13.4 |
| EBITA | 376.4 | 370.7 | 237.3 | 157.4 | 205.4 | 136.2 | 120.6 | 180.0 |
| EBITA margin | 33.1% | 33.5% | 25.5% | 21.3% | 28.8% | 21.2% | 21.4% | 36.1% |
| Amortization of intangibles | 77.5 | 74.1 | | | 58.7 | | | 29.4 |
| EBIT [+] | 298.9 | 296.6 | 237.3 | 157.4 | 146.7 | 136.2 | 120.6 | 150.6 |
| EBIT growth | 0.8% | 25.0% | 50.7% | 7.3% | 7.7% | 12.9% | -19.9% | 2.4% |
| EBIT margin | 26.3% | 26.8% | 25.5% | 21.3% | 20.5% | 21.2% | 21.4% | 30.2% |
| Interest expense, net [+] | 7.8 | 10.5 | 13.5 | 18.6 | 21.1 | 9.8 | 7.1 | 1.5 |
| Interest expense | 11.2 | 11.3 | 14.0 | 19.2 | 21.7 | 10.2 | 7.4 | 1.7 |
| Interest income | 3.4 | 0.8 | 0.5 | 0.6 | 0.6 | 0.4 | 0.3 | 0.2 |
| Other income (expense), net | 47.5 | 15.3 | -75.6 | 137.7 | -13.6 | -0.4 | -1.6 | -1.6 |
| Pre-tax income | 338.7 | 301.4 | 148.2 | 276.5 | 112.0 | 126.0 | 112.0 | 147.5 |
| Income taxes | 53.2 | 38.3 | 8.6 | 47.2 | 15.9 | -0.2 | 35.9 | 43.0 |
| Tax rate | 15.7% | 12.7% | 5.8% | 17.1% | 14.2% | | 32.0% | 29.2% |
| Minority interest | 0.2 | -9.0 | -0.8 | | | | | |
| Net income | 285.3 | 272.1 | 140.4 | 229.3 | 96.1 | 126.2 | 76.1 | 104.5 |
| Net margin | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.6% | 13.5% | 20.9% |
| |
| Basic EPS [+] | $1.81 | $1.73 | $0.91 | $6.00 | $2.54 | $3.37 | $2.04 | $2.81 |
| Growth | 4.7% | 91.4% | -84.9% | 136.0% | -24.5% | 65.1% | -27.4% | -3.3% |
| Diluted EPS [+] | $1.76 | $1.66 | $0.87 | $5.82 | $2.47 | $3.31 | $2.03 | $2.80 |
| Growth | 6.3% | 91.2% | -85.1% | 135.6% | -25.5% | 63.4% | -27.5% | -3.3% |
| |
| Dividends per share [+] | $0.32 | $0.32 | $0.32 | $1.28 | $1.28 | $1.28 | $1.28 | $1.28 |
| Growth | 0.0% | 0.0% | -75.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% |
| |
| Shares outstanding (basic) [+] | 157.2 | 156.9 | 155.0 | 38.2 | 37.8 | 37.5 | 37.3 | 37.2 |
| Growth | 0.2% | 1.2% | 305.7% | 1.1% | 0.8% | 0.4% | 0.3% | 0.3% |
| Shares outstanding (diluted) [+] | 161.9 | 164.1 | 161.9 | 39.4 | 38.9 | 38.1 | 37.5 | 37.3 |
| Growth | -1.4% | 1.3% | 311.0% | 1.3% | 2.2% | 1.5% | 0.5% | 0.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|